ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit

Core Viewpoint - Investors in Altimmune, Inc. have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred during the specified class period [1] Group 1: Class Action Details - The class period for the lawsuit is defined as December 1, 2023, to April 26, 2024 [1] - The deadline for potential lead plaintiffs to file is set for July 5, 2024 [1] Group 2: Allegations Against Altimmune - The complaint alleges that Altimmune overstated the potential of its drug pemvidutide compared to competing GLP-1 agonists based on misleading efficacy and tolerability results from the MOMENTUM Trial [2] - It is claimed that the results of the MOMENTUM Trial were less significant for pemvidutide's clinical and commercial prospects than previously communicated to investors [2] - The allegations further state that the company exaggerated its prospects for securing a strategic partner for pemvidutide's development, leading to materially misleading statements about its business and operations [2]